Sinopulmonary aspergillosis in children with hematological malignancy

Minerva Pediatrica

Volumn 58, Issue 3, 2006, Pages 319-324

  Gulen, H ^a,d   Erbay, A ^b   Gulen, F ^c   Kazanci, E ^b   Vergin, C ^b   Demir, E ^c   Tanac, R ^c  

^a CELAL BAYAR UNIVERSITY MEDICAL FACULTY   (Turkey)

^b DR BEHÇET UZ CHILDREN'S HOSPITAL   (Turkey)

^c EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d NONE   (Italy)

Author keywords

Aspergillus; Child; Neoplasms

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; CYTARABINE; ITRACONAZOLE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ANAMNESIS; ARTICLE; ASPERGILLUS FLAVUS; BRONCHIECTASIS; CASE REPORT; CHILD; CLINICAL FEATURE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LOBECTOMY; LUNG ASPERGILLOSIS; LUNG BIOPSY; LUNG LAVAGE; MALE; NASAL BIOPSY; PARANASAL SINUS DISEASE; PHYSICAL EXAMINATION; PROGNOSIS; RADIODIAGNOSIS; RESPIRATORY FAILURE; SOFT TISSUE DISEASE; SPUTUM CYTODIAGNOSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BURKITT LYMPHOMA; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; ITRACONAZOLE; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; LUNG DISEASES, FUNGAL; MALE; PROGNOSIS; RADIOGRAPHY, THORACIC; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33747593095     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. nd ed. Oxford: Blackwell Science; 1997.
2. Levin LA, Avery R, Shore JW, Woog JJ, Baker AS. The spectrum of orbital aspergillosis: a clinicopathological review. Surv Ophthalmol 1996;41:142-54.
3. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW et al. Practice guidelines for diseases caused by aspergillus. Clin Infect Dis 2000;30:696-709.
4. Glasmacher A, Prentice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005;56 Suppl 1:23-32.
5. Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003;21:4615-26.
6. Ruhnke M, Bohme A, Buchheidt D, Donhuijsen K, Einsele H, Enzensberger R et al.; Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Diagnosis of invasive fungal infections in hematology and oncology. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82:141-8.
7. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M et al. Fungal infections in cancer patients:an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992;11:99-109.
8. Kim K, Lee MH, Kim J, Lee KS, Kim SM, Jung MP et al. Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Am J Hematol 2002;71:75-9.
9. Donnelly JP. Symptoms and diagnosis of nosocomial fungal infections in the immunocompromised host. Drug Resist Update 2002;7:192-9.
10. Erjavec Z, Verweij PE. Recent progress in the diagnosis of fungal infections in the immunocompromised host. Drug Resist Update 2002;5:3-10.
11. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47.
12. Potter M. Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemother 2005;56:49-54.
13. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al.; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
14. Van Cutsem J, Van Gevren F, Janssen PA. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987;9:15-32.
15. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994;97:135-44.
16. Erratum in: Am J Med 1994;97:497.
17. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-13.
18. Schwartz S, Thiel E. Update on the treatment of cerebral aspergillosis. Ann Haematol 2004;3:42-4.
19. Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005;50:196-205.
20. Herbrecht R, Nivoix Y, Fohrer C, Natarajan-Ame S, Letscher-Bru V. Management of systemic fungal infections: alternatives to itraconazole. J Antimicrob Chemother 2005;56 Suppl 1:39-48.
21. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med 2002;347:408-15.
22. Leenders AC, Daenen S, Jansen RL, Hop WC. Lowenberg B, Wijermans PW et al. Lipsomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103:205-12.
23. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66.
24. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172-7.
25. Subira M, Martino R, Franquet T, Puzo C, Altes A, Sureda A et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica 2002;87:528-34.
26. el Omri H, Mili-Fathallah A, Amara H, Ben Youssef Y, Garrouche A, Ben Said M et al. Invasive aspergillosis in the leukemic patient. Rev Mal Respir 2001;18(6 Pt 1):607-14.
27. Denning DW. Therapeutic outcome in invasive Aspergillosis. Clin Infect Dis 1996;23:608-15.